Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
Agendia Presents Data Supporting Predictive Claim For Breast Cancer Dx
December 17, 2008
This new data, which Agendia plans to submit to the US Food and Drug Administration to update the label for MammaPrint, would put the Netherlands-based firm squarely in competition with Genomic Health, whose Oncotype DX is currently the only test designed to predict both chemotherapy benefit and breast cancer recurrence. However, Oncotype DX has not been cleared by the FDA.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- NIH Awards Lucigen $2.8M SBIR Grant for POC Influenza Test
May 23, 2012 / GenomeWeb Daily News - Genentech Takes Personalized Medicine Approach in Pursuing Amyloid Hypothesis for Alzheimer's Drug
May 23, 2012 / Pharmacogenomics Reporter - Agilent to Strengthen Personalized Rx Foothold with $2.2B Dako Acquisition
May 23, 2012 / Pharmacogenomics Reporter - NIH Study Finds DTC Genetic Risk Info Doesn't Increase Patients' Use of Healthcare Services
May 23, 2012 / Pharmacogenomics Reporter - Vertex Says CF Patients with Double F508del Mutation Showing Improvement in VX-809/Kalydeco Trial
May 23, 2012 / Pharmacogenomics Reporter